Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mirjam van der Spek"'
Autor:
Willem M. de Vos, Jorn H. A. Hartman, Geert R. D'Haens, Noortje G. Rossen, Jan G. Tijssen, Mirjam van der Spek, Mark Löwenberg, Elisabeth M. H. Mathus-Vliegen, Susana Fuentes, Gijs R. van den Brink, Cyriel Y. Ponsioen, Ann Duflou, Erwin G. Zoetendal
Publikováno v:
Gastroenterology, 149(1), 110-118
Gastroenterology 149 (2015) 1
Gastroenterology, 149(1), 110-118.e4. W.B. Saunders Ltd
Gastroenterology 149 (2015) 1
Gastroenterology, 149(1), 110-118.e4. W.B. Saunders Ltd
Background & Aims Several case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). We assessed the efficacy and safety of FMT for patients with UC in a double-blind randomized trial. Methods Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77da07fe0158c4d4f1f7817118391bea
https://doi.org/10.1053/j.gastro.2015.03.045
https://doi.org/10.1053/j.gastro.2015.03.045
Autor:
Erwin G. Zoetendal, Katri Korpela, Noortje G. Rossen, Cyriel Y. Ponsioen, Susana Fuentes, Geert R. D'Haens, Willem M. de Vos, Steven Aalvink, Laura Huuskonen, Jorn H. A. Hartman, Jarkko Salojärvi, Mirjam van der Spek
Publikováno v:
ISME Journal 11 (2017)
ISME Journal, 11, 1877-1889
ISME journal, 11(8), 1877-1889. Nature Publishing Group
ISME Journal, 11, 1877-1889
ISME journal, 11(8), 1877-1889. Nature Publishing Group
Faecal microbiota transplantation (FMT) may contribute towards disease remission in ulcerative colitis (UC), but it is unknown which factors determine long-term effect of treatment. Here, we aimed to identify bacterial signatures associated with sust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2fa95a5e931fea9d6487dbede41ce2
https://pubmed.ncbi.nlm.nih.gov/28398347
https://pubmed.ncbi.nlm.nih.gov/28398347
A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis
Autor:
Cyriel Y. Ponsioen, Mirjam van der Spek, Erik A.J. Rauws, Fiebo J.W. ten Kate, Willemien G. Erkelens, Daan W. Hommes, Sander J. H. van Deventer, Pieter C. F. Stokkers
Publikováno v:
Journal of clinical gastroenterology, 42(5), 522-526. Lippincott Williams and Wilkins
Goals To evaluate the safety and efficacy of infliximab in patients with primary sclerosing cholangitis. Study In this double-blind, placebo-controlled study, 24 patients with primary sclerosing cholangitis were screened and randomly assigned in a 2:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a36be9c051bfa31efdec93c27353eccb
https://doi.org/10.1097/mcg.0b013e3181662426
https://doi.org/10.1097/mcg.0b013e3181662426
Autor:
Sander J. H. van Deventer, Hein J. Verberne, Mirjam van der Spek, Pieter C. F. Stokkers, Daniel W. Hommes, Maartje Deley
Publikováno v:
Scandinavian journal of gastroenterology, 41(2), 200-204. Informa Healthcare
OBJECTIVE: Decreased bone mineral density (BMD) is common in inflammatory bowel disease (IBD) and an increased risk of fractures has been reported. Guidelines state bisphosphonate treatment for IBD patients with decreased BMD, but orally available bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64361ebacd341d70b5bbc04473c2b77b
https://doi.org/10.1080/00365520500206467
https://doi.org/10.1080/00365520500206467
Autor:
S. Fuentes Enriquez de Salamanca, L. Mathus-Vliegen, W.M. de Vos, Mirjam van der Spek, Noortje G. Rossen, J. Tijssen, G.R. D' Haens, Jorn H. A. Hartman, E.G. Zoetendal, Cyriel Y. Ponsioen, Ann Duflou
Publikováno v:
Journal of Crohn's and Colitis. 9:S2-S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4416b178646535328b40975541450368
https://doi.org/10.1093/ecco-jcc/jju027.003
https://doi.org/10.1093/ecco-jcc/jju027.003
Autor:
Daan W. Hommes, Sander J. H. van Deventer, Mirjam van der Spek, Brenda H. van de Heisteeg, Joep F. Bartelsman
Publikováno v:
Inflammatory bowel diseases, 8(2), 81-86. John Wiley and Sons Inc.
The aim of this study was to report the 1-year clinical experience with infliximab treatment for Crohn's disease (CD) in the Netherlands. All 73 CD patients receiving infliximab infusions were prospectively followed during 1 year after the drugs' reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235521d1355bdac47bf5210625306f43
https://pure.amc.nl/en/publications/infliximab-treatment-for-crohns-disease-oneyear-experience-in-a-dutch-academic-hospital(7ad68990-0ab9-4838-83ae-d500497a06d8).html
https://pure.amc.nl/en/publications/infliximab-treatment-for-crohns-disease-oneyear-experience-in-a-dutch-academic-hospital(7ad68990-0ab9-4838-83ae-d500497a06d8).html
Autor:
Maartje Deley, Daniel Hemmes, Pieter Strokkers, Sander J. H. van Deventer, Tim C M A Schreuder, Chris J. J. Mulder, Mirjam van der Spek
Publikováno v:
Gastroenterology. 124:A520
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e47e15d4834bff708b5dbcf497747ac
https://doi.org/10.1016/s0016-5085(03)82631-8
https://doi.org/10.1016/s0016-5085(03)82631-8